AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06351709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold pack application
Description: For participants in the cold group, MSD ® brand cold pack gel (MVS Inmotion, MSD cold pack; Weftdijk 1502830, Belgium), 15 cm x 25 cm in size, was used to cool the extremities locally. The cold pack gel, kept in the freezer, was wrapped in a paper towel and placed on the knee area. Cold pack was applied to both knees for a total of 15 minutes.
Study NCT05908968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ELO water
Description: Drinking 1.5 litres daily of ELO water for 12 weeks
Study NCT03692481 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18FDG-PET scan
Description: 18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
Study NCT03619226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test patch
Description: the test patch consists of an adhesive patch
Study NCT02723370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff multi-component implementation strategy
Description: Staff will receive a multi-component implementation strategy for evidence based practices (EBPs) for colonoscopy, including split-dosing of bowel preparation, low literacy education materials for patients, and teach-back procedure. The implementation strategy includes a supply of low-literacy patient education materials for split-dosing the medication of their choice, poster and pocket-card with teach-back prompts, consultation to integrate materials and teach-back into workflow and a website with additional training and patient materials.
Study NCT03605069 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: QR-313
Description: QR-313 will be applied topically once daily for 8 weeks of treatment.
Study NCT03605069 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo will be applied topically once daily for 8 weeks of treatment.
Study NCT02811783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone Hydrochloride Lotion, 0.5%
Description: Topical TID for 2 weeks
Study NCT03647865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osseous Genioplasty
Description: Surgical Procedure that cuts the chin and reposition it in the correct place
Study NCT01421758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online social network enrollment plus education and self monitoring
Description: Participants are enrolled in an online social network designed to increase social support for physical activity and will self monitor physical activity and receive educational materials at a dedicated study website.
Study NCT01421758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web education control
Description: Participants will receive access to a dedicated study website where they can view educational materials related to physical activity
Study NCT04023448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transverse coloplasty pouch
Description: a transverse coloplasty pouch was performed before end to end colon-rectum (or anal canal) anastomosis
Study NCT04989400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate
Description: Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
Study NCT04989400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal.Group B: received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal. Then women in both groups had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
Study NCT04989400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal.Group B: received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal. Then women in both groups had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
Study NCT00798538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Services will be provided at one site
Description: Provision of buprenorphine induction and management, substance abuse counseling and HIV care will be provided at one clinic: the Waterbury Hospital Infectious Disease Clinic..
Study NCT02811783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lotion
Description: Topical TID for 2 weeks
Study NCT03165214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: coil
Description: microcoils
Study NCT03165214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hystoacryl glue
Description: hystoacryl mixed with lipidol
Study NCT00002514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: asparaginase
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Study NCT00798538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Services remain dispersed; i.e., not centralized to one-location or provider.
Description: Buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively.
Study NCT02824250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness-Based Stress Reduction (MBSR) is an 8-week classroom based program of mindfulness meditation and gentle yoga.
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thioguanine
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study NCT00002514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00002514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Study NCT00002514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Study NCT00002514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00002514 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT01800656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoloop-assisted ligate and let go colorectal polypectomy
Description: The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps without consecutive snare polypectomy.
Study NCT01800656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoloop-assisted snare colorectal polypectomy
Description: The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps with consecutive snare polypectomy.
Study NCT02044666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micronized Small Intestinal Submucosa (SIS)
Description: Micronized Small Intestinal Submucosa (SIS)
Study NCT02259140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Femoral Resection Arthroplasty
Description: Drains will be placed at the surgeon's discretion. Patients will be placed in skin traction on the operative side. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
Study NCT02259140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtrochanteric Valgus Osteotomy
Description: Drains will be placed at the surgeon's discretion. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
Study NCT00895687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Beginning dose of 150 mg taken by mouth daily for 21-day cycle.
Study NCT00895687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Beginning dose of 1. mg/m\^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
Study NCT01063842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol hydrochloride /acetaminophen
Description: 1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
Study NCT01063842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tramadol hydrochloride / acetaminophen and placebo
Description: 1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
Study NCT00673881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: choline fenofibrate
Description: 135 mg choline fenofibrate daily(oral, capsule)
Study NCT02510183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure Wrist Band
Description: Acupressure wrist band is a knitted elasticated wrist band, which operates by applying pressure on the P6 acupressure point on each wrist by means of a plastic stud.
Study NCT02510183 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupressure Wrist Band
Description: Placebo Acupressure Wrist Band is a knitted elasticated wrist band without a plastic stud.
Study NCT00278330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given by infusion
Study NCT00278330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT02342379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg
Study NCT05904002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pulmicort inhaler
Description: Each woman in both groups (A\&B) will receive pulmicort inhaler on needs.
Study NCT05904002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incentive spirometer treatment
Description: Each patient in group B will be instructed about the effects of incentive spirometer to gain their cooperation during the study course.
Study NCT04736225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Self-Titration Education Program
Description: The program contents of instruction included blood glucose self-monitoring, types of insulin, insulin self-administration, insulin dose titration, hyperglycemia or hypoglycemia self-management, diet, and exercise.a 20-min one-on-one training session from a nurse on how to self-titrate the insulin dose. The participants were taught to monitor their before-breakfast and before-dinner blood glucose levels at home and adjust their insulin doses accordingly.
Study NCT02342379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: 670mg/m2
Study NCT01895244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
Description: If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
Study NCT01719003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg bid
Description: Metformin 500 mg twice daily
Study NCT03816059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory virus testing
Description: All patients will be tested for respiratory viruses
Study NCT02958553 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: emPOWER Ankle
Description: The device is 510k cleared and is intended to replace a missing foot and ankle. The emPOWER Ankle is to be used exclusively for fittings of lower-extremity amputations as prescribed by a healthcare professional.
Study NCT04736225 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Self-Titration Education Program
Description: The program contents of instruction included blood glucose self-monitoring, types of insulin, insulin self-administration, insulin dose titration, hyperglycemia or hypoglycemia self-management, diet, and exercise.a 20-min one-on-one training session from a nurse on how to self-titrate the insulin dose. The participants were taught to monitor their before-breakfast and before-dinner blood glucose levels at home and adjust their insulin doses accordingly.
Study NCT02958553 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Subject's own passive prosthesis
Description: Devices will vary. Data gathered will form a baseline.
Study NCT02941744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: low fixed dose ipilimumab in combination with nivolumab
Study NCT02941744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: low fixed dose ipilimumab in combination with nivolumab
Study NCT03438565 — intervention group
Intervention type: DEVICE
Intervention: Asahi Chikai Black 18 neurovascular guidewire
Description: The Asahi Chikai Black 18 microguidewire employs a reverse tapered shaft with 0.018 tip and 0.014 proximal shaft, which provides additional support and tactile feedback.
Study NCT02345551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate-vigorous aerobic activity in line with published guidelines for cancer prevention
Study NCT04661774 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: reflexology massage
Description: reflexology massage of the foot zone implicated in diaphragm stimulation
Study NCT04661774 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sham massage
Description: traditional massage of the foot
Study NCT04336709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipex II
Description: Water based intracanal medicament
Study NCT04336709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metapex
Description: Oil based intracanal medicament
Study NCT00224835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Class
Description: Subjects randomized to this condition will attend 120 minute weekly sessions, plus a 7 hour retreat, for training in mindfulness meditation methods.
Study NCT00224835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Education Class
Description: Subjects in the disease education control condition will attend 8 weekly 60 minute sessions, plus a 7 hour special experience session, all of which will provide information about CAD in a didactic format.
Study NCT04929509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-assembling peptide
Description: each Curodont Repair applicator unit contains both Curolox technology for guided enamel regeneration and water for activation of the device, each box contains 10 applicators
Study NCT04929509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nanosilver fluoride varnish
Description: The synthesis of aqueous solution of silver nanoparticles will be carried out via the chemical reduction of silver nitrate (1 mL, 0.11 M) with sodium borohydride (0.3 mL, 0.8 M) and chitosan biopolymer (28.7 mL, 2.5 mg/mL) as a stabilizing agent. Sodium fluoride (10,147 ppm of fluorine) will be incorporated at the end of the experiment.
Study NCT01719003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg bid
Description: Metformin 1000 mg twice daily
Study NCT01719003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin low dose qd
Description: Empagliflozin low dose once daily
Study NCT01719003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin high dose qd
Description: Empagliflozin high dose once daily
Study NCT01719003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin low dose bid
Description: Empagliflozin low dose split twice daily
Study NCT00697151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin once a day, titrated to obtain an INR of 1.4 to 2.8; placebo aspirin once a day
Study NCT00697151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 325 mg once a day; placebo warfarin once a day
Study NCT01386255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: The final baclofen dose will be 0.7 mg/kg (to a maximum of 40 mg/day) divided in three doses.
Study NCT01719003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin high dose bid
Description: Empagliflozin high dose split twice daily
Study NCT01386255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo. No other names
Study NCT03766607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
Study NCT03766607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 8 mg/kg administered intravenously on days 1 and 15 every 28 days
Study NCT03766607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
Study NCT03043404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Description: TAVR with Lotus Valve Flex System
Study NCT02681835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC laryngoscope
Description: Intubation performed using C-MAC laryngoscope
Study NCT01260025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEDylated Recombinant Human Endostatin
Description: The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.
Study NCT02532712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 Soft-capsule (500mg/1 capsule)